STAT3-IN-1 is a novel, oral and selective STAT3 inhibitor with anticancer activity.

GYY 4137 morpholine salt (GYY-4137; GYY4137; ZYJ1122; ZYJ-1122) is a novel, water-soluble and slow releasing Hydrogen sulfide (H2S) donor.

inS3-54-A18 is a STAT3 inhibitor, suppressing tumor growth, metastasis and STAT3 target gene expression in vivo.

Stattic (6-Nitro-1-benzothiophene 1,1-dioxide) is a small molecule inhibitor of STAT3 that potently inhibits STAT3 activation and nuclear translocation with potential antineoplastic activity.

HO-3867 (HO3867; HO 3867), an analog of curcumin, is a novel, selective and potent STAT3 inhibitor with potential antitumor activity.

S3I-201 (also called S3I201; NSC74859; S3I 201; NSC-74859) is a cell permeable and selective Stat3 inhibitor with potential anticancer activity.

SH-4-54 (SH 454; SH4-54; SH454; SH-454) is a novel and potent STAT inhibitor with potential antineoplastic activity.

C188-9 is a novel, potent and orally bioavailable STAT3 inhibitor that binds to STAT3 with high affinity (KD=4.7±0.4 nM).

Nifuroxazide (Bacifurane; Diafuryl; Ambatrol; Antinal; Diarlidan) is a potent, cell-permeable and orally bioavailable nitrofuran-based antidiarrheal agent that effectively suppresses the activation of cellular STAT1/3/5 transcription activity with IC50 of 3 μM against IL-6-induced STAT3 activation in U3A cells.

HJC0152 hydrochloride is a novel, orally bioavailable and potent inhibitor of the signal transducers and activators of transcription 3 (STAT3).